<DOC>
	<DOCNO>NCT01184326</DOCNO>
	<brief_summary>This research study evaluate combination pazopanib everolimus patient malignancy metastatic unresectable standard curative palliative measure exist longer effective , metastatic locally advanced unresectable kidney cancer . In research study investigator test safety combination pazopanib everolimus well find appropriate dose use study .</brief_summary>
	<brief_title>Expanded Phase I Pazopanib Everolimus Advanced Solid Tumors Previously Treated Advanced Urothelial Cancer</brief_title>
	<detailed_description>- This protocol two part , Phase I Expansion Cohort . Once maximum tolerate dose identified Phase I portion , expansion cohort patient metastatic locally advanced unresectable kidney cancer enrol . - Each treatment cycle last 4 week participant take pazopanib everolimus orally daily .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Phase I : Participants must histologically confirm malignancy metastatic unresectable standard curative palliative measure exist longer effect . Expansion Cohort Only : Participants must histologically cytologically confirm metastatic locally advanced unresectable kidney cancer . Expansion Cohort Only : Participants must measurable disease , define least one lesion accurately measure least one dimension 20mm great conventional technique 10mm great spiral CT . Expansion Cohort Only : Previously treat least one antiangiogenic agent , include limited bevacizumab , sunitinib , sorafenib . No 4 line prior systemic therapy kidney cancer , mTOR pathway inhibitor RAD001 allow . 18 year age old Life expectancy great 3 month ECOG performance status 0 1 Normal organ marrow function outline protocol Able swallow oral medication Resolution preexist toxicity prior therapy NCI CTCAE v4.0 grade 1 less Women eligible participate nonchild bear potential agrees use adequate contraception Female subject lactate discontinue nursing prior first dose study drug refrain nursing throughout treatment period 14 day follow last dose study drug A male female partner childbearing potential must use barrier method contraception abstinence study Participants chemotherapy radiotherapy within 4 week prior enter study tho recover adverse event due agent administer 4 week earlier . Current treatment leuprolide GnRH agonists permit Phase 1 portion study . Participants may receive study agent . Prior RAD001 pazopanib therapy History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except individual previously treat CNS metastasis , asymptomatic , requirement steroid antiseizure medication 6 week prior first dose study drug . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate pazopanib everolimus History follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting ; myocardial infarction ; unstable angina ; coronary artery bypass graft surgery ; symptomatic peripheral vascular disease ; Class III IV congestive heart failure Poorly control hypertension History cerebrovascular accident , pulmonary embolism , untreated deep venous thrombosis within past 6 month Prior major surgery trauma within 28 day prior first dose study drug , and/or recover effect surgery , and/or presence nonhealing wound , fracture ulcer , patient may require surgery course treatment Evidence active bleeding bleed diathesis Known endobronchial lesion involvement large pulmonary vessel tumor Hemoptysis within 6 week first dose study drug Clinically significant gastrointestinal abnormality may increase risk GI bleed Expansion Cohort Only : Currently active second malignancy nonmelanoma skin cancer Presence uncontrolled infection Liver disease chronic cirrhosis , active hepatitis chronic persistent hepatitis Uncontrolled diabetes Pregnant breastfeed Chronic treatment systemic corticosteroid immunosuppressive agent Treatment strong CYP3A4 inhibitor Treatment strong CYP3A4 inducer Patients receive immunization attenuate live vaccine within one week study entry study period Prolongation correct QT interval &gt; 480msecs History malabsorption syndrome , disease significantly affect gastrointestinal function major resection stomach small bowel could interfere absorption , distribution , metabolism , excretion study drug Any ongoing toxicity prior anticancer therapy great grade 1 and/or progress severity . Any serious and/or preexist medical , psychiatric , condition could interfere subject safety , obtain informed consent compliance study procedure HIVpositive individual combination antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>RAD001</keyword>
	<keyword>pazopanib</keyword>
	<keyword>everolimus</keyword>
	<keyword>advanced cancer</keyword>
</DOC>